Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5

Futu NewsJan 8 22:31 · Ratings

Cautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab's Efficacy and Dosing

TipRanksJan 8 18:48 · Ratings

ACELYRIN Is Maintained at Neutral by Citigroup

Dow JonesJan 8 04:09 · Ratings

Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3

BenzingaJan 8 03:58 · Ratings

Nasdaq Down 1.5%; RPM Posts Upbeat Results

BenzingaJan 8 01:05

Dow Surges Over 100 Points; US Trade Deficit Widens In November

BenzingaJan 7 23:00